Contineum Therapeutics, Inc. (CTNM) Stock Score, Valuation & Financial Research

Contineum Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CTNM

Contineum Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 12.65. These figures are a research snapshot, not a buy or sell recommendation.

What Contineum Therapeutics, Inc. does

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Contineum Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its pipeline of small molecule therapies for inflammatory and fibrotic diseases.

Products and services

  • The company is developing a pipeline of small molecule drug candidates, including PIPE-791, an LPA1 receptor antagonist for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and CTX-343.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party contract research organizations to conduct its clinical trials and preclinical studies. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturing organizations for the production of its drug candidates for clinical trials. Source

Business strengths to evaluate

  • Proprietary pipeline of small molecule therapies targeting inflammatory and fibrotic diseases. Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses for the foreseeable future. Source
  • Significant need for additional capital to fund research and development and clinical trials. Source
  • Dependence on third-party manufacturers and clinical research organizations. Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CTNM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 12.65
Market capitalization:
475.91M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -57.56M
Free cash flow:
USD -55.54M
Cash:
USD 14.71M
Total debt:
USD 6.57M
EPS:
USD -1.73

What stands out

  • Free cash flow is USD -55.54M, negative for the stored period.
  • The balance sheet shows USD 14.71M of cash versus USD 6.57M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.14M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CTNM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CTNM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CTNM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CTNM to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CTNM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CTNM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.